000309607 001__ 309607
000309607 005__ 20260202155815.0
000309607 0247_ $$2doi$$a10.3171/2025.9.JNS251254
000309607 0247_ $$2pmid$$apmid:41616295
000309607 0247_ $$2ISSN$$a0022-3085
000309607 0247_ $$2ISSN$$a1933-0693
000309607 037__ $$aDKFZ-2026-00257
000309607 041__ $$aEnglish
000309607 082__ $$a610
000309607 1001_ $$aWeller, Jonathan$$b0
000309607 245__ $$aAssociation of a diffuse phenotype on MRI with shorter overall survival in patients with astrocytoma CNS WHO grades 2 and 3.
000309607 260__ $$aCharlottesville, Va.$$bAmerican Assoc. of Neurological Surgeons$$c2026
000309607 3367_ $$2DRIVER$$aarticle
000309607 3367_ $$2DataCite$$aOutput Types/Journal article
000309607 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770044282_1634685
000309607 3367_ $$2BibTeX$$aARTICLE
000309607 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309607 3367_ $$00$$2EndNote$$aJournal Article
000309607 500__ $$a#DKTKZFB9# / epub
000309607 520__ $$aGliomas can appear radiologically diffuse or sharply delineated on MRI. This can be quantified by the T1/T2 ratio, a quotient of the T1 hypointense to T2 hyperintense tumor volume. In patients with CNS WHO grade 2 and 3 isocitrate dehydrogenase (IDH)-mutant astrocytomas, resectability has been shown to be limited in cases of low T1/T2 ratios, that is, in diffusely appearing astrocytomas. The authors set out to investigate if a diffuse phenotype on MRI is associated with overall survival beyond resectability.Retrospective data sets from two university hospitals (Sahlgrenska University Hospital, Gothenburg, Sweden; LMU University Hospital, Munich, Germany) were screened for patients diagnosed with 2021 CNS WHO grade 2 and 3 astrocytomas by biopsy between 2003 and 2021. Patients having undergone tumor resection were excluded. Tumor volumes were segmented and the T1/T2 ratio was calculated. Propensity score matching (nearest-neighbor matching, 1:1) was used.One hundred nineteen patients with CNS WHO grade 2 (n = 77, 65%) or grade 3 (n = 42, 35%) IDH-mutant astrocytomas were included in the study. In unadjusted analyses, survival was not significantly shorter in patients with a T1/T2 ratio ≤ 0.33 (144 vs 126 months; HR 0.61, 95% CI 0.34-1.1; p = 0.09). Propensity score matching (Karnofsky Performance Status, CNS WHO 2021 grade, contrast enhancement on MRI, and T2 tumor volume) yielded 29 pairs. Here, significantly shorter overall survival was observed in patients with a T1/T2 ratio ≤ 0.33 (160 vs 132 months; HR 0.44, 95% CI 0.19-1.00; p = 0.05). In multivariate analysis, only the T1/T2 ratio persisted as a prognostic factor (HR 0.48, 95% CI 0.25-0.92; p = 0.03).A diffuse phenotype on MRI seems to be associated with shorter survival times in patients with CNS WHO grade 2 and 3 astrocytomas. These findings warrant further investigation in prospective data sets.
000309607 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000309607 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309607 650_7 $$2Other$$aIDH mutation
000309607 650_7 $$2Other$$abiopsy
000309607 650_7 $$2Other$$adiagnostic technique
000309607 650_7 $$2Other$$alow-grade glioma
000309607 650_7 $$2Other$$aoncology
000309607 650_7 $$2Other$$aprognosis
000309607 650_7 $$2Other$$arisk factor
000309607 650_7 $$2Other$$atumor volume
000309607 7001_ $$aHarba, Dima$$b1
000309607 7001_ $$aKuschel, Luis$$b2
000309607 7001_ $$aThiele, Frederic$$b3
000309607 7001_ $$aKatzendobler, Sophie$$b4
000309607 7001_ $$aCorell, Alba$$b5
000309607 7001_ $$aDénes, Anna$$b6
000309607 7001_ $$aSchmutzer-Sondergeld, Michael$$b7
000309607 7001_ $$ade Dios, Eddie$$b8
000309607 7001_ $$aRingel, Florian$$b9
000309607 7001_ $$0P:(DE-HGF)0$$aTonn, Joerg Christian$$b10
000309607 7001_ $$aJakola, Asgeir S$$b11
000309607 773__ $$0PERI:(DE-600)2026156-1$$a10.3171/2025.9.JNS251254$$gp. 1 - 8$$pnn$$tJournal of neurosurgery$$vnn$$x0022-3085$$y2026
000309607 909CO $$ooai:inrepo02.dkfz.de:309607$$pVDB
000309607 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000309607 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000309607 9141_ $$y2026
000309607 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000309607 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000309607 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000309607 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-05
000309607 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000309607 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
000309607 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-05
000309607 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000309607 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000309607 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000309607 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROSURG : 2022$$d2024-12-05
000309607 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-05
000309607 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000309607 980__ $$ajournal
000309607 980__ $$aVDB
000309607 980__ $$aI:(DE-He78)MU01-20160331
000309607 980__ $$aUNRESTRICTED